1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Shandong Wit Dyne Health Co.,Ltd.

Shandong Wit Dyne Health Co.,Ltd.

000915.SZ
Shandong Wit Dyne Health Co.,Ltd.CN flagShenzhen Stock Exchange
24.78
CNY
-0.65
- -
5.81BMarket Cap
Shandong Wit Dyne Health Co.,Ltd.
000915.SZ
(Shenzhen Stock Exchange)

Recent

price

24.78

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.38
3.06
3.52
4.67
5.88
5.29
6.62
7.56
6.47
7.67
7.77
8.64
10
10.61
9.11
9.5
9.2
Revenue per Share
0.3
0.4
0.52
0.65
0.93
0.65
0.85
1.04
0.55
0.87
1.24
1.62
2.25
2.5
2.2
2.28
2.23
Basic EPS, GAAP
0.64
0.35
0.45
0.64
0.82
0.9
1.16
1.06
1.73
0.3
2.7
2.71
4.73
4.8
3.78
5.21
-0.25
Free Cash Flow per Basic Share
0.06
0.07
0.04
0.11
0.11
0.09
0.09
0.12
0.22
0.31
0.28
0.45
0.8
0.8
2.5
2.5
0.5
Dividend per Share
1.55
1.94
2.42
2.98
3.82
4.37
5.1
5.94
6.16
6.73
7.63
8.75
10.22
11.92
11.61
11.38
11.08
Book Value per Share
1.83
2.46
3.22
4.15
5.56
6.32
7.5
8.91
9.02
10.04
11.71
13.6
16.46
18.35
18.01
17.64
16.63
Tangible Book Value per Share
235
234
236
234
234
233
233
234
236
235
234
235
234
234
234
235
234
Basic Weighted Avg Shares
560
717
830
1,095
1,374
1,233
1,545
1,767
1,526
1,800
1,821
2,027
2,341
2,484
2,134
2,228
2,151
Sales/Revenue/Turnover
32.17
29.65
35.62
33.83
32.02
28.42
27.69
30.39
19.77
22.51
32.55
38.2
48.75
51.27
54.64
53.55
54.91
Operating Margin (%)
26
29
29
29
35
36
41
43
48
57
65
69
68
73
73
71
- -
Depreciation Expense
71
94
122
153
217
152
198
243
130
204
291
380
527
585
516
535
521
Net Income, GAAP
13.52
13.23
13.93
14.05
13.98
13.99
13.63
14.29
11.24
13.36
13.27
14.23
13.92
14.96
14.61
14.78
14
Effective Tax Rate (%)
12.59
13.08
14.65
13.99
15.82
12.36
12.84
13.76
8.5
11.34
15.97
18.76
22.51
23.56
24.16
24.01
24.24
Profit Margin (%)
31
163
293
397
658
654
786
922
1,133
1,258
1,618
1,967
2,630
3,112
3,093
3,076
2,779
Working Capital
86
70
51
32
2
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
650
769
946
1,160
1,482
1,680
1,949
2,219
2,341
2,567
2,935
3,399
4,061
4,497
4,412
4,351
4,079
Total Equity
18.46
20.52
25.22
27.16
26.66
18.1
19.6
21.42
11.6
14.24
18.68
20.93
26.1
24.97
21.85
22.53
24.08
Return on Invested Capital (%)
3.04
4.29
3.32
3.73
4.18
3.18
2.69
1.83
0.96
2.16
1.88
1.88
1.58
1.07
0.59
0.99
0.71
Return on Capital (%)
21.35
22.92
23.75
24.15
27.31
15.94
17.95
18.85
9.12
13.46
17.27
19.8
23.7
22.58
18.71
19.85
19.88
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
234
234
234
Market Capitalization
6,600
6,607
8,264

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
3,511
3,746
3,197
Cash, Cash Equivalents & STI
3,079
3,124
2,769
Accounts Receivable, Net
70
79
79
Inventories
71
75
78
Total Current Liabilities
418
803
418
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.21%
8.55%
-1.4%
Free Cash Flow
88.71%
18.57%
38.06%
Net Income, GAAP
17.82%
14.46%
3.78%
Sales/Revenue/Turnover
6.84%
4.65%
4.4%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
572
583
224
757
2,134
2025
616
554
626
- -
2,228
2026
412
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.72
- -
- -
- -
2.2
2025
0.78
- -
- -
- -
2.28
2026
0.47
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2.5
2025
- -
- -
- -
- -
2.5
2026
- -
- -
- -
- -
- -
Similar Companies
Applied Biosciences Corp. (APPB)
Novartis India Limited (NOVARTIND.NS)
Hana Pharm Co., Ltd. (293480.KS)
Ortin Global Ltd (ORTINGLOBE.BO)
Sunshine Biopharma, Inc. (SBFM)
Medicamen Biotech Limited (MEDICAMEQ.NS)
Business
Shandong Wit Dyne Health Co.,Ltd. Shandong Wit Dyne Health Co.,Ltd. (000915.SZ) engages primarily in the research, development, production and sales of children's medicines and health products in China. The company offers a broad portfolio of pharmaceutical and nutritional products including iquesin, dexin, dyne iron, dyne calcium, dyne zinc, pediatric ibuprofen suppositories, oral rehydration solution (III), dimercaptan capsules, tomoxetine hydrochloride oral solution, desloratadine oral solution, simethicone emulsion, sodium valproate oral solution, azithromycin granules, licorice zinc granules, compound calcium carbonate, vitamin AD drops, dextran iron granules, rifaximin dry suspension, DHA series (DHA, DHA+ARA, DHA+PS), probiotic powder series, minerals soft gel series (calcium D, zinc, iron), oral liquid series (various minerals, calcium and zinc), chewable tablet series (multivitamin, calcium DK) and recombinant collagen gel/ointment dressing products; it also provides environmental protection solutions such as chlorine dioxide equipment, flue gas desulfurization services and wastewater treatment through subsidiaries. Founded in 1993 and headquartered in Jinan, Shandong Province, the company operates mainly in the domestic Chinese market with approximately 1,759 employees and targets pediatric healthcare segments including antibiotics, supplements, digestive aids and chronic condition treatments. In recent developments, a subsidiary obtained exclusive general distribution rights for Manlejing under the Noble Ren brand as of 2024, and the company changed its Chinese name to Shandong Huatai Dyne Health Co., Ltd. in April 2021 to reflect its focus on child health; it continues to emphasize innovation in pediatric medicines while maintaining environmental operations.